- Home
- AVDX vs SYRE Comparison
AVDX vs SYRE Comparison
Compare AVDX & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDX
- SYRE
- Stock Information
- Founded
- AVDX 2000
- SYRE 2013
- Country
- AVDX United States
- SYRE United States
- Employees
- AVDX N/A
- SYRE 60
- Industry
- AVDX EDP Services
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- AVDX Technology
- SYRE Health Care
- Exchange
- AVDX Nasdaq
- SYRE Nasdaq
- Market Cap
- AVDX 1.6B
- SYRE 1.3B
- IPO Year
- AVDX 2021
- SYRE 2016
- Fundamental
- Price
- AVDX $9.22
- SYRE $21.29
- Analyst Decision
- AVDX Hold
- SYRE Strong Buy
- Analyst Count
- AVDX 15
- SYRE 8
- Target Price
- AVDX $11.63
- SYRE $51.50
- AVG Volume (30 Days)
- AVDX 1.2M
- SYRE 550.7K
- Earning Date
- AVDX 02-26-2025
- SYRE 03-03-2025
- Dividend Yield
- AVDX N/A
- SYRE N/A
- EPS Growth
- AVDX N/A
- SYRE N/A
- EPS
- AVDX N/A
- SYRE N/A
- Revenue
- AVDX $427,566,000.00
- SYRE N/A
- Revenue This Year
- AVDX $17.41
- SYRE $168.62
- Revenue Next Year
- AVDX $10.36
- SYRE $47.61
- P/E Ratio
- AVDX N/A
- SYRE N/A
- Revenue Growth
- AVDX 17.84
- SYRE N/A
- 52 Week Low
- AVDX $7.38
- SYRE $20.13
- 52 Week High
- AVDX $13.56
- SYRE $47.97
- Technical
- Relative Strength Index (RSI)
- AVDX 25.78
- SYRE 40.66
- Support Level
- AVDX $9.80
- SYRE $21.61
- Resistance Level
- AVDX $10.17
- SYRE $23.04
- Average True Range (ATR)
- AVDX 0.29
- SYRE 1.43
- MACD
- AVDX -0.11
- SYRE -0.03
- Stochastic Oscillator
- AVDX 3.24
- SYRE 22.03
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.